Galectin Therapeutics (GALT) Cash from Operations (2010 - 2026)

Galectin Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 3866000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 49.79% year-over-year to 3866000.0; the TTM figure through Mar 2026 stood at 20066000.0 (up 46.3% YoY), while the FY2025 annual figure was 23900000.0, up 42.78% from the prior year.
• Cash from Operations was 3866000.0 for Q1 2026 at Galectin Therapeutics, up from 6100000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 3500000.0 in Q3 2025 to a low of 12791000.0 in Q4 2024.
• Historically, Cash from Operations has averaged 7858176.47 across 5 years, with a median of 7700000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 170.02% in 2024, then jumped 59.19% in 2025.
• A 5-year view of Cash from Operations shows it stood at 7239000.0 in 2022, then surged by 34.56% to 4737000.0 in 2023, then tumbled by 170.02% to 12791000.0 in 2024, then surged by 52.31% to 6100000.0 in 2025, then soared by 36.62% to 3866000.0 in 2026.
• The last three Cash from Operations figures came in at 3866000.0 (Q1 2026), 6100000.0 (Q4 2025), and 3500000.0 (Q3 2025), per Business Quant data.